KEVIN GAREY to Clinical Trials, Phase I as Topic
This is a "connection" page, showing publications KEVIN GAREY has written about Clinical Trials, Phase I as Topic.
Connection Strength
0.033
-
Ridinilazole: a novel therapy for Clostridium difficile infection. Int J Antimicrob Agents. 2016 Aug; 48(2):137-43.
Score: 0.033
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.